Daniel V. Moller

Ørestads Boulevard 5
Copenhagen, 2300, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Journal: The New England journal of medicine

Published: April 08, 2024

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

Journal: Lancet (London, England)

Published: February 08, 2024

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Journal: The New England journal of medicine

Published: August 25, 2023

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.

Journal: Nature medicine

Published: July 10, 2023

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

Journal: JACC. Heart failure

Published: April 16, 2023

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: June 28, 2021

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.

Journal: Cardiovascular diabetology

Published: August 14, 2019

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Journal: Diabetes care

Published: July 31, 2017

Obese hypertensive men have plasma concentrations of C-reactive protein similar to that of obese normotensive men.

Obese hypertensive men have plasma concentrations of C-reactive protein similar to that of obese normotensive men.

Journal: American journal of hypertension

Published: March 11, 2014

Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men.

Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men.

Journal: American journal of hypertension

Published: September 13, 2013

Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men.

Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: May 15, 2013

MT-CYB mutations in hypertrophic cardiomyopathy.

MT-CYB mutations in hypertrophic cardiomyopathy.

Journal: Molecular genetics & genomic medicine

Published: January 24, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026